MCID: CRC006
MIFTS: 55

Carcinoid Syndrome

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Carcinoid Syndrome

MalaCards integrated aliases for Carcinoid Syndrome:

Name: Carcinoid Syndrome 52 58 17 32
Malignant Carcinoid Syndrome 58 71
Carcinoid Tumor 52 71
Carcinoid Tumor No Icd-O Subtype 71
Carcinoid Tumor Syndrome 52
Carcinoid Tumors 42

Classifications:

Orphanet: 58  
Rare endocrine diseases


Summaries for Carcinoid Syndrome

NIH Rare Diseases : 52 Carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). Affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias ), and wheezing . In later stages, carcinoid syndrome may damage the heart valves, resulting in symptoms of congestive heart failure . The condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream. Only 10% of people with carcinoid tumors develop carcinoid syndrome; most have advanced stage carcinoid tumors that have spread to the liver. Treatment generally involves addressing the underlying carcinoid tumor and medications to alleviate symptoms.

MalaCards based summary : Carcinoid Syndrome, also known as malignant carcinoid syndrome, is related to appendix carcinoid tumor and pulmonary blastoma. An important gene associated with Carcinoid Syndrome is SDHD (Succinate Dehydrogenase Complex Subunit D), and among its related pathways/superpathways are Relaxin signaling pathway and Neuroscience. The drugs Everolimus and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and liver, and related phenotypes are night sweats and episodic abdominal pain

MedlinePlus : 42 Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. In later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. Surgery is the main treatment for carcinoid tumors. If they haven't spread to other parts of the body, surgery can cure the cancer.

Wikipedia : 74 Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary... more...

Related Diseases for Carcinoid Syndrome

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 823)
# Related Disease Score Top Affiliating Genes
1 appendix carcinoid tumor 33.9 SYP ENO2 CHGA
2 pulmonary blastoma 31.8 SYP SST CHGA CALCA
3 carcinoid tumors, intestinal 31.7 SYP SST MEN1 ENO2 CHGA
4 goblet cell carcinoid 31.3 ENO2 CHGA
5 serotonin syndrome 31.1 SST PYY MEN1 IFNA2 HTR3A GHRH
6 atrophic gastritis 31.1 SST MEN1 CHGA
7 horseshoe kidney 30.6 SYP ENO2 CHGA
8 small cell carcinoma 30.6 SYP ENO2 CHGA CALCA
9 ileus 30.5 SST NTS CALCA
10 lung benign neoplasm 30.5 SYP ENO2 CHGA
11 benign teratoma 30.4 SYP ENO2 CHGA
12 appendix adenocarcinoma 30.4 SYP CHGA
13 pituitary tumors 30.3 SST MEN1 IGF1
14 meckel diverticulum 30.2 SST CHGA
15 conn's syndrome 30.2 SST MEN1 IGF1 GHRH CHGA CALCA
16 glucagonoma 30.2 SST CHGA
17 ectopic cushing syndrome 30.2 SYP SST
18 pancreatic somatostatinoma 30.2 SST CALCA
19 large cell neuroendocrine carcinoma 30.2 SYP ENO2 CHGA
20 ampulla of vater neoplasm 30.2 SYP SST ENO2 CHGA
21 hyperthyroidism 30.1 SST IGF1 CALCA
22 neurofibromatosis, type i 30.1 SST SDHD MEN1
23 middle ear adenoma 30.0 SYP ENO2 CHGA
24 tubular adenocarcinoma 30.0 SYP ENO2 CHGA
25 small intestine neuroendocrine neoplasm 30.0 SST MEN1
26 pain agnosia 30.0 NTS HTR3A CALCA
27 pituitary adenoma 30.0 SST MEN1 IGF1 GHRH CHGA
28 rectum neuroendocrine neoplasm 29.9 SYP SST
29 hyperprolactinemia 29.9 SST IGF1 GHRH
30 insulinoma 29.9 SST MEN1 CHGA
31 mediastinal cancer 29.9 SYP ENO2 CHGA
32 gastrinoma 29.9 SYP SST MEN1 CHGA
33 cellular ependymoma 29.9 SYP MEN1
34 acromegaly 29.9 SST MEN1 IGF1 GHRH
35 jejunal neoplasm 29.9 SYP ENO2
36 mccune-albright syndrome 29.8 SST MEN1 IGF1
37 hyperinsulinemic hypoglycemia 29.8 SST MEN1 ENO2
38 sclerosing hemangioma 29.8 SYP ENO2 CHGA CALCA
39 irritable bowel syndrome 29.8 SST PYY HTR3A
40 lung oat cell carcinoma 29.8 SYP ENO2 CHGA CALCA
41 benign ependymoma 29.7 SYP MEN1 ENO2
42 pulmonary sclerosing hemangioma 29.7 SYP ENO2 CHGA
43 gastric ulcer 29.6 VEGFA SST CALCA
44 gangliocytoma 29.6 SYP GHRH ENO2
45 thyroid gland medullary carcinoma 29.6 SST MEN1 CHGA CALCA
46 hypoglycemia 29.6 VEGFA SST IGF1 GHRH
47 thyroid carcinoma, familial medullary 29.6 SST MEN1 CHGA CALCA
48 pituitary adenoma, prolactin-secreting 29.6 SST MEN1 IGF1 CHGA
49 cancer-associated retinopathy 29.6 VEGFA ENO2
50 thymoma 29.6 VEGFA SYP SST ENO2

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome

Symptoms & Phenotypes for Carcinoid Syndrome

Human phenotypes related to Carcinoid Syndrome:

58 31 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 night sweats 58 31 frequent (33%) Frequent (79-30%) HP:0030166
2 episodic abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002574
3 intestinal carcinoid 58 31 frequent (33%) Frequent (79-30%) HP:0006723
4 erythematous plaque 58 31 frequent (33%) Frequent (79-30%) HP:0025474
5 protracted diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0004385
6 small intestine carcinoid 58 31 frequent (33%) Frequent (79-30%) HP:0006722
7 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
8 elevated hepatic transaminase 58 31 occasional (7.5%) Occasional (29-5%) HP:0002910
9 asthma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002099
10 tricuspid regurgitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005180
11 facial telangiectasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007380
12 heart murmur 58 31 occasional (7.5%) Occasional (29-5%) HP:0030148
13 palpitations 58 31 occasional (7.5%) Occasional (29-5%) HP:0001962
14 epiphora 58 31 occasional (7.5%) Occasional (29-5%) HP:0009926
15 chronic noninfectious lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002730
16 right ventricular failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001708
17 increased serum serotonin 58 31 occasional (7.5%) Occasional (29-5%) HP:0003144
18 bronchospasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0025428
19 abnormal b-type natriuretic peptide level 58 31 occasional (7.5%) Occasional (29-5%) HP:0031138
20 rhinorrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0031417
21 myopathy 58 31 very rare (1%) Very rare (<4-1%) HP:0003198
22 paraganglioma 58 31 very rare (1%) Very rare (<4-1%) HP:0002668
23 hepatic necrosis 58 31 very rare (1%) Very rare (<4-1%) HP:0002605
24 lack of bowel sounds 58 31 very rare (1%) Very rare (<4-1%) HP:0030145
25 atypical pulmonary carcinoid tumor 58 31 very rare (1%) Very rare (<4-1%) HP:0030446
26 pulmonary carcinoid tumor 58 Occasional (29-5%)
27 carcinoid tumor 58 Obligate (100%)

MGI Mouse Phenotypes related to Carcinoid Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.96 ENO2 GHRH HTR3A NPY NTS PYY
2 growth/size/body region MP:0005378 9.93 CHGA ENO2 GHRH HTR3A IGF1 MEN1
3 homeostasis/metabolism MP:0005376 9.7 CHGA GHRH HTR3A IGF1 MEN1 NPY
4 nervous system MP:0003631 9.44 CHGA ENO2 GHRH HTR3A IGF1 MEN1

Drugs & Therapeutics for Carcinoid Syndrome

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
2
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
3 Immunosuppressive Agents Phase 4
4
Tranexamic Acid Approved Phase 3 1197-18-8 5526
5
Ondansetron Approved Phase 3 99614-02-5 4595
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
10
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
11
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
12
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
14 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6
15 Hemostatics Phase 3
16 Antifibrinolytic Agents Phase 3
17 Coagulants Phase 3
18 Cola Phase 3
19 Liver Extracts Phase 3
20 Dermatologic Agents Phase 3
21 Psychotropic Drugs Phase 3
22 Anti-Anxiety Agents Phase 3
23 glucocorticoids Phase 3
24 Anti-Inflammatory Agents Phase 3
25 Antipsychotic Agents Phase 3
26 Anesthetics Phase 3
27 Narcotics Phase 3
28 Analgesics Phase 3
29 Analgesics, Opioid Phase 3
30 Anesthetics, General Phase 3
31 Anesthetics, Intravenous Phase 3
32 Immunoglobulins Phase 3
33 Antibodies Phase 3
34 Antibodies, Monoclonal Phase 3
35 Immunoglobulins, Intravenous Phase 3
36 Mitogens Phase 3
37 Endothelial Growth Factors Phase 3
38 Immunoglobulin G Phase 3
39 Antineoplastic Agents, Immunological Phase 2, Phase 3
40 Angiogenesis Inhibitors Phase 2, Phase 3
41 Micronutrients Phase 2, Phase 3
42 Vitamins Phase 2, Phase 3
43 Antidotes Phase 2, Phase 3
44 Vitamin B Complex Phase 2, Phase 3
45 Folate Phase 2, Phase 3
46 Nutrients Phase 2, Phase 3
47 Trace Elements Phase 2, Phase 3
48 Vitamin B9 Phase 2, Phase 3
49 Protective Agents Phase 2, Phase 3
50 5-hydroxytryptophan Phase 3

Interventional clinical trials:

(show top 50) (show all 197)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
3 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
4 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
5 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
6 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) Completed NCT02026063 Phase 3 Telotristat etiprate
7 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
8 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
9 A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
10 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
11 A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues. Completed NCT00690430 Phase 3 Pasireotide;Octreotide
12 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
13 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
15 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
16 A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Active, not recruiting NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
17 A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
18 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
19 Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Terminated NCT00227136 Phase 3 5-Hydroxy-Tryptamine
20 Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Withdrawn NCT04065165 Phase 3 Telotristat Ethyl;Lanreotide
21 Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
22 A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS Unknown status NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
23 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
24 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
25 Phase II Study of Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
26 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
27 A Prospective, Randomized Trial of Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas Unknown status NCT00993356 Phase 2 Preoperative lanreotide treatment
28 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
29 A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid Completed NCT00002470 Phase 2 fluorouracil
30 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
31 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
32 Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
33 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
34 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
35 An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
36 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
37 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
38 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
39 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
40 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
41 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
42 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
43 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
44 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
45 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
46 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
47 A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors Completed NCT00328497 Phase 2 Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
48 A Phase II Study of Axitinib in Advanced Carcinoid Tumors Completed NCT01435122 Phase 2 Axitinib
49 EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
50 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT02575300 Phase 2 Ibrutinib

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2b

Genetic Tests for Carcinoid Syndrome

Anatomical Context for Carcinoid Syndrome

MalaCards organs/tissues related to Carcinoid Syndrome:

40
Heart, Lung, Liver, Small Intestine, Skin, Ovary, Appendix

Publications for Carcinoid Syndrome

Articles related to Carcinoid Syndrome:

(show top 50) (show all 2135)
# Title Authors PMID Year
1
Neuroendocrine Tumors of the Pancreatobiliary and Gastrointestinal Tracts. 42
32402306 2020
2
Strumal carcinoid tumor of the ovary: A rare case report. 42
31770214 2019
3
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. 42
31527867 2019
4
Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection. 61
32509817 2020
5
A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. 61
32157590 2020
6
Solitary myocardial metastasis from neuroendocrine tumor: surgical resection as curative surgery. 61
32556900 2020
7
Cardiac metastasis of neuroendocrine tumor of the thymus diagnosed by cardiac magnetic resonance T1 mapping: a case report. 61
32558603 2020
8
Carcinoid Tumors of the Orbit and Ocular Adnexa. 61
32496392 2020
9
Serotonin-Secreting Neuroendocrine Tumours of the Pancreas. 61
32384679 2020
10
Regarding "TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World". 61
32420675 2020
11
The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition. 61
32429294 2020
12
Early Outcomes of Surgery for Carcinoid Heart Disease. 61
31383543 2020
13
Primary neuroendocrine tumour of the left ventricle. 61
31562505 2020
14
Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. 61
32032719 2020
15
A primary neuroendocrine tumor of the left ventricle presenting with diarrhea-an unusual experience and literature review. 61
32245475 2020
16
Management of Small Bowel Neuroendocrine Tumors. 61
32151357 2020
17
Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. 61
31414209 2020
18
CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome. 61
32102919 2020
19
Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). 61
32157626 2020
20
Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study. 61
32132510 2020
21
Liver embolisation for patients with neuroendocrine neoplasms: systematic review. 61
32172229 2020
22
Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. 61
32146619 2020
23
Anesthesia for Endocrine Emergencies. 61
32008649 2020
24
Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. 61
32152781 2020
25
Carcinoid Syndrome: A Review. 61
32257725 2020
26
Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms. 61
32108932 2020
27
Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia. 61
31605174 2020
28
Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival - A Systematic Literature Review. 61
32097914 2020
29
Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review. 61
32036806 2020
30
Flushing as atypical initial presentation of functional gallbladder neuroendocrine carcinoma: A case report. 61
32103876 2020
31
Inhibition of serotonin synthesis: A novel therapeutic paradigm. 61
31629717 2020
32
Primary Renal Carcinoid Tumor: Report of Two Cases. 61
32240087 2020
33
High-grade well-differentiated neuroendocrine tumour of the cecum diagnosed following incisional hernia repair: a case report. 61
32577092 2020
34
Colonic Goblet Cell Carcinoid: Rarity of a Rarity! A Case Report and Review of Literature. 61
32155405 2020
35
Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells. 61
31319410 2020
36
Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. 61
32322270 2020
37
[Small bowel neuroendocrine tumours: to be considered in the differential diagnosis of unexplained abdominal pain and diarrhoea]. 61
32186828 2020
38
Direct costs of carcinoid syndrome diarrhea among adults in the United States. 61
31885426 2019
39
Multidisciplinary team management of carcinoid heart disease. 61
31751305 2019
40
Description of a transient proximal tubulopathy induced by amino acids perfusion in peptide receptor radionuclide therapy: A case report. 61
31876733 2019
41
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. 61
31406974 2019
42
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. 61
31987306 2019
43
Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues. 61
32304367 2019
44
TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. 61
31189618 2019
45
The Outcome of Primary Hepatic Neuroendocrine Tumors: A Single-Center Experience. 61
31889752 2019
46
Idiopathic anaphylaxis. 61
31690394 2019
47
Carcinoid Heart Disease: a Comprehensive Review. 61
31745664 2019
48
Carcinoid Heart Disease: A Guide for Clinicians. 61
31587790 2019
49
[Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system]. 61
31594011 2019
50
Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors. 61
31593022 2019

Variations for Carcinoid Syndrome

ClinVar genetic disease variations for Carcinoid Syndrome:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SDHD NM_003002.4(SDHD):c.149A>G (p.His50Arg)SNV Conflicting interpretations of pathogenicity 6909 rs11214077 11:111958677-111958677 11:112087953-112087953

Expression for Carcinoid Syndrome

Search GEO for disease gene expression data for Carcinoid Syndrome.

Pathways for Carcinoid Syndrome

Pathways related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.15 VEGFA SST IGF1 GHRH
2 11.99 SYP NPY ENO2 CALCA
3 11.17 VEGFA IGF1 ENO2
4 10.7 VEGFA SYP IGF1
5 10.62 PYY NPY

GO Terms for Carcinoid Syndrome

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VEGFA SST PYY NTS NPY IGF1
2 terminal bouton GO:0043195 9.33 SYP GHRH CALCA
3 extracellular space GO:0005615 9.32 VEGFA SST PYY NPY IGF1 IFNA2
4 neuronal dense core vesicle GO:0098992 9.26 NPY CHGA

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.93 SST PYY NTS NPY GHRH CALCA
2 cell-cell signaling GO:0007267 9.67 SST IFNA2 GHRH CALCA
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 VEGFA IGF1 IFNA2
4 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 IGF1 GHRH
5 regulation of blood pressure GO:0008217 9.43 NPY CHGA CALCA
6 intestinal epithelial cell differentiation GO:0060575 9.4 PYY NPY
7 response to heat GO:0009408 9.33 SST IGF1 CALCA
8 feeding behavior GO:0007631 9.13 PYY NPY CALCA
9 neuropeptide signaling pathway GO:0007218 8.92 PYY NTS NPY CALCA

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.26 PYY NTS NPY GHRH
2 hormone activity GO:0005179 9.1 SST PYY NPY IGF1 GHRH CALCA

Sources for Carcinoid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....